The nerve to expect more. The nerve to redefine patient expectations.

The VNS Therapy® System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients 4 years of age and older with partial onset seizures that are refractory to antiepileptic medications

VNS Therapy® treatment in adult patients

Medication alone is not enough in managing drug-resistant epilepsy

Patients with poorly controlled epilepsy are at more than a 10× greater risk of premature death versus those who achieve seizure freedom¹

Fewer than 1 in 10 patients achieves seizure freedom with an anti-seizure medication (ASM) after 2 or more failures²

Rates of intolerable adverse effects and seizure freedom with ASMs have been stagnant despite 12+ medications being approved in the last 30 years^3,4

VNS Therapy™ Can Provide Improvements in Seizure Control*

VNS Therapy™ Can De-Intensify and Seizures and Provide Improvements in Seizure Control*

mean follow-up 13 months (N=51)

p<0.001

59% reported ≥ 50% reduction in seizures

41% reported ≥ 80% reduction in seizures

*Data is from devices with AutoStim Mode enabled, which is only available in models 106, 1000, and 1000-D.

VNS Therapy™ significantly reduces depressive symptoms in DRE patients

VNS Therapy™ can reduce mood-related symptoms in patients with DRE

84% of patients experienced a reduction of depressive symptoms*^₁

*In a prospective study, K-BDI scores decreased by 32% between baseline and follow-up

Change in MADRS score: 38% reduction after VNS Therapy

Change in BDI score: 42% reduction after VNS Therapy

*VNS Therapy is not indicated to treat depression in drug-resistant epilepsy patients.

The nerve to choose a treatment that won't contribute to CNS adverse effects

VNS Therapy™ has demonstrated safety and effectiveness as an adjunctive treatement option that can improve your patients’ seizure control without contributing to anti-seizure medication (ASM) toxicity.

As an adjunctive treatment
with no drug interactions, VNS Therapy may help reduce the dosage of ASMs in your
patient’s regimen.¹³

References: 1. Thurman DJ, Logroscino G, Beghi E, et al. Epilepsia. 2017;58(1):17-26. 2. Mula M, Zaccara G, Galimberti CA, et al. Epilepsia. 2019;60:1114-1123. 3. Alsfouk BAAA, Brodie MJ, Walters M, et al. JAMA Neurol. 2020;77(5):574-581. 4. Chen Z, Brodie MJ, Liew D, et al. JAMA Neurol. 2018;75(3):279-286. 5. Data on file, LivaNova, Inc., Houston, TX. 6. Datta P, Galla KM, Sajja K, et al. Epilepsy Behav. 2020;111:107280. doi: 10.1016/j.yebeh.2020.107280. 7. Elliot RE, Morsi A, Tanweer O, et al. Epilepsy Behav. 2011;20(3):478-483. 8. Englot DJ, Hassnain KH, Rolston JD, et al. Epilepsy Behav. 2017;66:4-9. 9. Spindler P, Bohlmann K, Straub HB, et al. Seizure. 2019;69:77-79. 10. Ryvlin P, So EL, Gordon CM, et al. Epilepsia. 2018;59(3):562-572. 11. Ben-Menachem E. J Clin Neurophysiol. 2001;18(5):415-418. 12. Morris GL, Mueller WM. Neurology. 1999;53(7):1731-1735. 13. Epilepsy Patient’s Manual for Vagus Nerve Stimulation, LivaNova, Inc., Houston, TX.

Choose a country

For ALL other countries, please click here.

The nerve to expect more. The nerve to redefine patient expectations.

The VNS Therapy® System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients 4 years of age and older with partial onset seizures that are refractory to antiepileptic medications

Medication alone is not enough in managing drug-resistant epilepsy

Patients with poorly controlled epilepsy are at more than a 10× greater risk of premature death versus those who achieve seizure freedom¹

Fewer than 1 in 10 patients achieves seizure freedom with an anti-seizure medication (ASM) after 2 or more failures²

Rates of intolerable adverse effects and seizure freedom with ASMs have been stagnant despite 12+ medications being approved in the last 30 years^3,4

The nerve to enable adult patients to overcome seizures

The latest generation of VNS Therapy® with AutoStim* is designed with seizure control in mind—with the ability to customize treatment to meet the needs of your patients with drug-resistant epilepsy (DRE)

VNS Therapy™ can reduce the impact of seizures and can help improve post-ictal recovery

VNS Therapy™ Can Provide Improvements in Seizure Control*

VNS Therapy™ Can De-Intensify and Seizures and Provide Improvements in Seizure Control*

mean follow-up 13 months (N=51)

p<0.001

59% reported ≥ 50% reduction in seizures

41% reported ≥ 80% reduction in seizures

*Data is from devices with AutoStim Mode enabled, which is only available in models 106, 1000, and 1000-D.

VNS Therapy® response improves over time with a 76% mean reduction in seizures at 10 years

The nerve to improve a patient’s quality of life

3 out of 4 patients experienced improvements in overall QoL⁸

VNS Therapy™ can reduce mood-related symptoms in patients with DRE

The nerve to choose a treatment that won't contribute to CNS adverse effects

VNS Therapy^™ has demonstrated safety and is well tolerated

VNS Therapy™ has no neurotoxic effects or drug interactions^11,13

Access resources to support your practice and patients

Watch real-life patient testimonials

VNS Therapy^™ Safety Profile

Choose a country

For ALL other countries, please click here.

The nerve to expect more. The nerve to redefine patient expectations.

The VNS Therapy® System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients 4 years of age and older with partial onset seizures that are refractory to antiepileptic medications

Patients with poorly controlled epilepsy are at more than a 10× greater risk of premature death versus those who achieve seizure freedom1

Fewer than 1 in 10 patients achieves seizure freedom with an anti-seizure medication (ASM) after 2 or more failures2

Rates of intolerable adverse effects and seizure freedom with ASMs have been stagnant despite 12+ medications being approved in the last 30 years3,4

The nerve to enable adult patients to overcome seizures

The latest generation of VNS Therapy® with AutoStim* is designed with seizure control in mind—with the ability to customize treatment to meet the needs of your patients with drug-resistant epilepsy (DRE)

VNS Therapy™ can reduce the impact of seizures and can help improve post-ictal recovery

VNS Therapy™ Can Provide Improvements in Seizure Control*

VNS Therapy™ Can De-Intensify and Seizures and Provide Improvements in Seizure Control*

mean follow-up 13 months (N=51)

p<0.001

59% reported ≥ 50% reduction in seizures

41% reported ≥ 80% reduction in seizures

*Data is from devices with AutoStim Mode enabled, which is only available in models 106, 1000, and 1000-D.

VNS Therapy® response improves over time with a 76% mean reduction in seizures at 10 years

The nerve to improve a patient’s quality of life

3 out of 4 patients experienced improvements in overall QoL8

VNS Therapy™ can reduce mood-related symptoms in patients with DRE

The nerve to choose a treatment that won't contribute to CNS adverse effects

VNS Therapy™ has demonstrated safety and is well tolerated

VNS Therapy™ has no neurotoxic effects or drug interactions11,13

Access resources to support your practice and patients

Watch real-life patient testimonials

VNS Therapy™ Safety Profile

Patients with poorly controlled epilepsy are at more than a 10× greater risk of premature death versus those who achieve seizure freedom¹

Fewer than 1 in 10 patients achieves seizure freedom with an anti-seizure medication (ASM) after 2 or more failures²

Rates of intolerable adverse effects and seizure freedom with ASMs have been stagnant despite 12+ medications being approved in the last 30 years^3,4

3 out of 4 patients experienced improvements in overall QoL⁸

VNS Therapy^™ has demonstrated safety and is well tolerated

VNS Therapy™ has no neurotoxic effects or drug interactions^11,13

VNS Therapy^™ Safety Profile